Stories

Sweden’s political deadlock is now affecting the future of nicotine taxation across the EU. The October vote on the revised Tobacco Excise Directive has been postponed until November, while uncertainty over Sweden’s next government raises questions about whether an agreement can be reached.

At the centre of the disagreement is Sweden’s opposition to EU-wide tax rules that could treat nicotine pouches similarly to combustible tobacco. Sweden has argued for taxation that reflects differences in product risk, consistent with its tobacco harm reduction approach. The outcome could have significant implications for the affordability of smoke-free alternatives and the future direction of European nicotine policy.

Sweden and Kazakhstan illustrate how different tobacco control strategies can shape smoking trends and public health outcomes. Sweden has made significant progress in reducing smoking prevalence, supported by the availability of safer nicotine alternatives. Kazakhstan, meanwhile, has pursued a more restrictive approach to nicotine products, raising questions about the impact of limited access to smoke-free options.

The contrast highlights the importance of risk-proportionate regulation and the role consumer choice can play in reducing smoking-related harm.

Health insurers could play a much greater role in reducing smoking-related disease in the United States. Despite smoking cessation being among the most cost-effective medical interventions, fewer than half of smokers report receiving advice or assistance to quit.

Recent developments, including cheaper cessation medications, new clinical performance measures and growing evidence on safer nicotine alternatives, offer an opportunity to change that. Integrating tobacco harm reduction into health insurance programmes could improve patient outcomes while reducing long-term healthcare costs. The priority is not simply treating smoking-related disease, but investing in preventing it.

Traditional nasvay production in Kyrgyzstan offers a closer look at a smokeless tobacco product with deep roots in Central Asia. Its preparation, ingredients and manufacturing conditions raise important questions about product quality, toxicant exposure and consumer safety. The latest GSTHR video explores how nasvay is made, highlighting why understanding traditional nicotine products is essential to developing effective, evidence-based tobacco harm reduction strategies.

A nicotine “market freeze” would lock Europe into today’s options instead of allowing better, lower-risk products to emerge. Innovation should not be given a free pass, but it should be assessed through evidence, standards and real-world impact rather than blocked in advance. Freezing the market could leave cigarettes protected while future smoke-free alternatives are kept out. Europe needs regulation that can manage risk without closing the door on progress.

Anti-nicotine campaigns rarely present themselves as propaganda; they present themselves as protection. That is why scrutiny matters. Funding networks, advocacy strategies and institutional alliances can shape which evidence is amplified, which voices are excluded and how safer nicotine products are framed to the public. A serious public health debate should be able to follow the influence behind the message, especially when the result may be fewer options for adults trying to leave cigarettes behind.

Tobacco harm reduction does not require nicotine to be innocent. It requires honesty about where the greatest harm comes from. Nicotine can cause dependence and should not be promoted casually, but cigarettes are deadly because they burn tobacco and expose users to toxic smoke. The case for safer nicotine products rests on reducing that exposure — not on pretending nicotine has no risks.

CAPHRA welcomes an Australian opposition proposal to legalise and regulate adult access to vapes and nicotine pouches without prescriptions, but warns against linking it to an 80% cigarette excise cut. The package includes $200 million for enforcement and is projected to raise $8 billion over four years. Australia’s government rejects the proposal, while public health groups warn cheaper cigarettes could increase smoking. CAPHRA argues regulated alternatives—not cheaper cigarettes—would address illicit markets, citing New Zealand’s declining smoking rates since vaping regulation. It urges Canberra to assess legalisation separately from the contentious cigarette tax debate.

Brussels’ nicotine debate has a transparency problem when public money funds organisations that then echo the Commission’s preferred line. The article points to a “market freeze” backed by several health ministers that would restrict future nicotine products while cigarettes remain available. That should concern anyone interested in evidence-based regulation. Public health policy needs independent scrutiny, consumer voices and open funding trails — especially when decisions could limit lower-risk alternatives for millions of adults who smoke.

Nicotine entering wellness culture creates a communication challenge public health cannot ignore. A product may be smoke-free and far less harmful than cigarettes, but that does not make nicotine a lifestyle supplement or a harmless productivity tool. The clearest message is also the most nuanced: non-combustible nicotine can matter for smokers moving away from combustion, while non-users should not be encouraged to start. Risk communication needs to hold both truths at once.